PHARMACY

Thrifty White named 2016 Pharmacy Innovator

BY DSN STAFF

DSN has named Thrifty White Pharmacy its 2016 Pharmacy Innovator award winner. DSN publisher Eric Savitch and editor in chief/associate publisher Rob Eder presented the award to Thrifty White president and CEO Bob Narveson, COO Tim Weippert and key members of the company’s pharmacy leadership team at an exclusive reception at Minneapolis’ Butcher and the Boar restaurant.

(To read more about this year's Pharmacy Innovator award recipient, click here.)

The award, presented annually by the editors and publishers of DSN, honors a retail pharmacy company, pharmacy executive or pharmacy team for contributions that have helped to advance the practice of pharmacy, expand the role of the community pharmacist and/or to help improve patient care and drive better health outcomes.

“By that measure, there are few companies that have done more to advance the pharmacy profession than Thrifty White,” Eder explained. “The work it has done to pioneer medication synchronization is a perfect example; the appointment-based model is enabling Thrifty White’s pharmacists to practice at the top of their license, optimizing pharmacist-patient engagement and improving medication adherence.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Aurobindo launches its Nexium generic

BY David Salazar
EAST WINDSOR, N.J. — Aurobindo Pharma USA on Tuesday announced the launch of its Nexium generic.  has launched its generic of Nexium (esomeprazole magnesium) delayed-release capsules. 
 
The drug is indicated to treat gastroesophageal reflux disease reduce the risk of NSAID-associated gastric ulcer. Aurobindo’s generic will be available in 20- and 40-mg dosage strengths. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

QuintilesIMS Institute report examines global spending trends through 2020

BY David Salazar
DANBURY, Conn. and RESEARCH TRIANGLE PARK, N.J. — The latest report from the QuintilesIMS Institute for Health for Healthcare Informatics is taking a look at how spending on medicines will change through 2021. The “Outlook for Global Medicines Through 2021: Balancing Cost and Value” report projects that total global spending will be close to $1.5 trillion on an invoice price basis through 2021. As this happens, the compound annual growth rate is expected to moderate, rising between 4% and 7% by 2021, compared to the 9% CAGR in 2014 and 2015. 
 
“The outlook for medicine spending growth reflects a more sustainable level for health systems, following the unexpectedly high growth seen in recent years,” Quintiles IMS Institute SVP and executive director Murray Aitken, said. “At the same time, the astonishing level of scientific advances for disease treatments inevitably will place ongoing pressure on funding for medicines—requiring value-based assessments that balance patient needs and pricing levels with competing healthcare priorities.”
 
The projected spending total reflects a global increase of $387 billion in spending on a constant-dollar basis. Over the next five years, the United States will continue to be the world’s largest pharmaceutical market, making up 53% of forecasted growth, with China in second place contributing 12% of the growth.  
 
Like the global market, the U.S. market’s growth will moderate in the next five years, going from 12% in 2015 to  6-7% in 2016, with an expected growth rate of 6% to 9% through 2021 on an invoice price basis. The decline, according to the report, is due to the dropoff in growth driven by hepatitis C treatments and the impact of patent expiries, including the introduction of biosimilars, following years of brands facing little new generic competition. 
 
But even as growth slows, the QuintilesIMS Institute expects the next five years to see historically high numbers of new drug launches. Through 2021, it’s projected that the more than 2,000 drugs in the late-stage pipeline will bring 45 new active substances to market annually. Much of these will focus on unmet needs in such disease areas as cancer, autoimmune disorders and metabolic and nervous system disorders. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?